(2,4-difluorophenylamino)-*N*-(2-methylbut-3-yn-2-yl)nicotinamide, 2-(2,4-difluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 5-fluoro-2-(3-fluorophenylamino)-*N*-(2-methylbut-3-yn-2-yl)nicotinamide, 5-fluoro-2-(3-fluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 5-chloro-2-(3,3-difluorocyclobutylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(3-cyanophenylamino)-5-fluoro-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(2-fluoro-5-methoxyphenylamino)-*N*-(2-methylbut-3-yn-2-yl)nicotinamide, 2-(2-fluoro-5-methoxyphenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(3-cyano-4-fluorophenylamino)-*N*-(2-methylbut-3-yn-2-yl)nicotinamide, 2-(3-cyano-4-fluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(3-cyano-5-fluorophenylamino)-*N*-(2-methylbut-3-yn-2-yl)nicotinamide, 2-(3-fluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)-nicotinamide, 2-(2-fluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(3,5-difluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(3-cyano-5-fluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(2-chloro-5-methoxyphenylamino)-*N*-(2-methylbut-3-yn-2-yl)nicotinamide, 2-(2-chloro-5-methoxyphenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, *N*-(3-methylpent-1-yn-3-yl)-2-(phenylamino)nicotinamide, 2-(4,4-difluorocyclohexylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(3-chloro-4-methoxyphenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(4-fluoro-3-methoxyphenylamino)-*N*-(2-methylbut-3-yn-2-yl)-nicotinamide, 2-(4-fluoro-3-methoxyphenylamino)-*N*-(3-methylpent-1-yn-3-yl)-nicotinamide, 2-(3,4-difluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, 2-(4-chloro-3-methoxyphenylamino)-*N*-(2-methylbut-3-yn-2-yl)nicotinamide, 2-(4-chloro-3-methoxyphenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide, or 2-(4-fluorophenylamino)-*N*-(3-methylpent-1-yn-3-yl)nicotinamide

13. The compound according to any one of claims 1 to ~~10~~12 for use as a medicament.

~~14. The compound according to any one of claims 1 to 11 for use in the treatment of a disorder, condition or disease mediated by TRPA1 receptor activity.~~

~~15. The compound according to claim 12, wherein the disorder, condition or disease is neuropathic pain, pain in diabetic polyneuropathy, postoperative pain, cancer pain, migraine, asthma, COPD, cough, pain in osteoarthritis, pain in rheumatoid arthritis,~~

~~inflammatory bowel disease, or diabetes.~~

~~16. A method for the treatment of a disorder, condition, or disease mediated by TRPA1 receptor activity, which method comprises administering to a mammal in need of such treatment an effective amount of at least one compound according to claim 1.~~

~~17. The method according to claim 14, wherein the disorder, condition or disease is neuropathic pain, pain in diabetic polyneuropathy, postoperative pain, cancer pain, migraine, asthma, COPD, cough, pain in osteoarthritis, pain in rheumatoid arthritis, inflammatory bowel disease, or diabetes.~~

~~18.~~14. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to ~~10~~12 and a pharmaceutically acceptable carrier, diluents, and/or excipient.

~~19.~~15. The pharmaceutical composition according to claim ~~16~~14, wherein the composition further comprises at least one other active ingredient.